References
- 1. Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, et al. Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Vol. 2, Journal of virus eradication. 2016. p. 243–50.10.1016/S2055-6640(20)30879-7
- 2. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45–55.
- 3. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65–70.10.1001/archneurol.2007.31276318718195140
- 4. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009 Jul;23(11):1359–66.10.1097/QAD.0b013e32832c4152270654919424052
- 5. Bacellar H, Muñoz A, Miller EN, Cohen BA, Besley D, Selnes OA, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology. 1994 Oct;44(10):1892–900.10.1212/WNL.44.10.1892
- 6. Rachlis AR. (1998) Neurologic manifestations of HIV infection. Postgrad Med.;103:1–11.
- 7. Institutul de Boli Infectioase “Prof. Dr. Matei Bals” Compartimentul pentru monitorizarea si evaluarea infectiei HIV/SIDA in Romania. Evolutia infectiei HIV/SIDA in Romania 31 Decembrie 2019. http://www.cnlas.ro/com_jce/date-statistice.html: Institutul de Boli Infectioase “Prof. Dr. Matei Bals”, 2019.
- 8. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011 Mar;25(6):F7-1210.1097/QAD.0b013e328345766f21412057